Evaluation of galectin-3 and other biochemical parameters in chronic kidney disease patients on hemodialysis in Erbil city


  • Zereen M. Abdullah Department of Clinical Biochemistry, College of Health Sciences, Hawler Medical University, Erbil, Iraq.
  • Kamaran Y. Mohammadamin Department of Clinical Biochemistry, University of Salahaddin, Erbil, Iraq.




Galectin-3, Chronic kidney disease, Hemodialysis


Background and objective: Chronic kidney disease represents a leading cause of death in many countries. End-stage renal disease is the final stage of chronic kidney disease, in which the kidneys are no longer function well enough for the patient to live without renal replacement therapy. Galectin-3 is a soluble beta-galactoside-binding lectin protein involved in the fibrosis of many solid organs, including the heart and kidney. This study aimed to evaluate galectin-3 and other biochemical parameters in hemodialysis patients.

Methods: The design is a cross-sectional study with a comparison group. A total of 70 chronic kidney disease patients on regular hemodialysis from Erbil Dialysis Center in Erbil City and 68 healthy subjects were enrolled. The serum levels of galectin-3 were determined by enzyme-linked immunosorbent assay method.

Results: The mean level of serum galectin-3 was non-significantly higher in hemodialysis patients compared to the control group (P = 0.594). However, the serum level of galectin-3 was significantly higher in hemodialysis patients with cardiovascular disease compared to hemodialysis patients without cardiovascular disease (P = 0.0220). Serum galectin-3 level was significantly higher in hemodialysis patients aged 36-50 and 51-70 years old compared to hemodialysis patients aged 20-35 years old (P = 0.013, P = 0.026), respectively.

Conclusion: Serum galectin-3 might be used as a biomarker for hemodialysis patients with cardiovascular disease.


Metrics Loading ...


Tsai M-T, Ou S-M, Chen H-Y, Tseng W-C, Lee K-H, Yang C-Y, et al. Relationship between circulating galectin-3, systemic inflammation, and protein-energy wasting in chronic hemodialysis patients. Nutrients. 2021; 13(8):2803. https://doi.org/10.3390/nu13082803

Brück K, Jager KJ, Dounousi E, Kainz A, Nitsch D, Ärnlöv J, et al. Methodology used in studies reporting chronic kidney disease prevalence: a systematic literature review. Nephrol Dial Transplant. 2015; 30(suppl_4):iv6–iv16. https://doi.org/10.1093/ndt/gfv131

Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, et al. Global prevalence of chronic kidney disease–a systematic review and meta-analysis. PLoS One. 2016; 11(7):e0158765. https://doi.org/10.1371/journal. pone.0158765

Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158(11):825–30. https://doi.org/10.7326/0003-4819-158-11-201306040-00007

Alexander N, Matsushita K, Sang Y, Ballew S, Mahmoodi BK, Astor BC, et al. Kidney measures with diabetes and hypertension on cardiovascular disease: the Atherosclerosis Risk in Communities Study. Am J Nephrol. 2015; 41(4-5):409–17. https://doi.org/10.1159/ 000433450

Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018; 33(suppl_3):iii28–34. https://doi.org/10.1093/ndt/gfy174

Vadakedath S, Kandi V. Dialysis: A Review of the Mechanisms Underlying Complications in the Management of Chronic Renal Failure. Cureus. 2017; 9(8):e1603. https://doi.org/10.7759/cureus. 1603

Abbasi MA, Chertow GM, Hall YN. End-stage renal disease. BMJ Clin Evid. 2010. https://pubmed.ncbi.nlm.nih.gov/21418665

Liu S, Wu Q, Zhang S, Wang Z, Liu H, Teng L, et al. Serum Galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study. BMC Nephrol. 2022; 23(1):1–9. https://doi.org/10.1186/s12882-021-02636-z

Bello AK, Okpechi IG, Osman MA, Cho Y, Htay H, Jha V, et al. Epidemiology of haemodialysis outcomes. Nat Rev Nephrol. 2022; 18(6):378–95. https://doi.org/10.1038/s41581-022-00542-7

Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y, et al. Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med. 2018; 41(2):599–614. https://doi.org/10.3892/ijmm.2017.3311

Sygitowicz G, Maciejak-Jastrzębska A, Sitkiewicz D. The diagnostic and therapeutic potential of galectin-3 in cardiovascular diseases. Biomolecules. 2021; 12(1):46. https://doi.org/ 10.3390/biom12010046

Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine-and cystatin C–based equations to estimate GFR without race.N Engl J Med. 2021; 385(19):1737–49. https://doi.org/10.1056/NEJMoa2102953

Sultan S, Nasir K, Qureshi R, Dhrolia M, Ahmad A. Assessment of the nutritional status of the hemodialysis patients by anthropometric measurements. Cureus. 2021; 13(10):e18605. https://doi.org/10.7759/cureus.18605

Thurlow JS, Joshi M, Yan G, Norris KC, Agodoa LY, Yuan CM, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am J Nephrol. 2021; 52(2):98–107. https://doi.org/ 10.1159/000514550

Ali SS, Naqshbandi VA, Sedeeq SA. Dialysis-Related Factors Affecting Activities of Daily Living in Patients on Hemodialysis in Erbil City. EJNM. 2021; 4(1):1–14. https://doi.org/10.15218/ejnm.2021.01

Li H, Wang S. Cardiovascular disease in hemodialysis patients. Hemodialysis: Intech Open. 2013. https://doi.org/10.5772/53071

Pandya D, Nagrajappa AK, Ravi KS. Assessment and correlation of urea and creatinine levels in saliva and serum of patients with chronic kidney disease, diabetes and hypertension–a research study. JCDR. 2016; 10(10):ZC58. https://doi.org/10.7860/JCDR/2016/20294.8651

Gupta K, Mahajan R. Coronary risk factors in maintenance hemodialysis patients: Who is the culprit–hemodialysis or chronic renal failure? Int J Appl Basic Med Res. 2011; 1(1):11. https://doi.org/10.4103/2229-516X.81973

Meijers WC, van der Velde AR, Ruifrok WP, Schroten NF, Dokter MM, Damman K, et al. Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. J Am Heart Assoc. 2014; 3(5):e000962. https://doi.org/10.1161/JAHA.114. 000962

De Boer RA, Van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, Van Gilst WH, Hillege HL, et al. The fibrosis marker galectin‐3 and outcome in the general population. J Intern Med. 2012; 272(1):55–64. https://doi.org/10.1111/j.1365-2796.2011.02476.x

Badve SV, Paul SK, Klein K, Clayton PA, Hawley CM, Brown FG, et al. The association between body mass index and mortality in incident dialysis patients. PLoS One. 2014; 9(12):e114897. https://doi.org/10.1371/journal.pone.0114897

Çelik G, Oc B, Kara I, Yılmaz M, Yuceaktas A, Apiliogullari S. Comparison of nutritional parameters among adult and elderly hemodialysis patients. Int J Med Sci. 2011; 8(7):628. https://doi.org/10.7150/ijms.8.628




How to Cite

M. Abdullah, Z., & Y. Mohammadamin, K. (2023). Evaluation of galectin-3 and other biochemical parameters in chronic kidney disease patients on hemodialysis in Erbil city. Zanco Journal of Medical Sciences (Zanco J Med Sci), 27(2), 176–183. https://doi.org/10.15218/zjms.2023.020



Original Articles